Advertisement

Topics

Companies Related to "A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies" [Most Relevant Company Matches] RSS

00:37 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies" found in our extensive corporate database of over 50,000 company records.

Showing "Study Delavirdine Mesylate Combination With Other Anti Drugs" Companies 1–25 of 2,600+

Relevant

Hanmi Pharmaceutical co., Ltd.

Hanmi Pharmaceutical is a Korea-based pharmaceutical company. The Company invests over 20 percent of its sales in R&D and has over 20 programs consisting of the novel long acting biologics including weekly Insulin, weekly to monthly GLP-1, and their combination for diabetes and obesity (collectively referred as Quantum Project), the novel targeted anti-can...


PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Inex Pharmaceuticals Corporation

INEX Pharmaceuticals Corporation is a biopharmaceutical company that utilizes proprietary drug delivery systems and therapeutic compounds to increase the effectiveness and reduce the side-effects of anti-cancer therapies. INEX's strategy has been to develop technology capable of making anti-cancer drugs more effective and reducing their side-effects, thus giving these drugs a competitive advantage...


Biopharmacopae

For centuries plants have been a very important source of medications. Less than 5% of the 300,00 plant species have ever been investigated for their medicinal properties. An estimated one-quarter of the prescription drugs contain active ingredients derived from plants. Widely used drugs from plant extracts include the antibiotic, immunosuppressant, and the anti-anti cancer agents. Global over the...

Synergys Biotherapeutics

Synergys is an early stage company developing multifunctional anti-vascularization antibody drugs targeting VEGF-alternative pathways. The Company’s most advanced product candidate, Anti-EGFR‐TAP (SYN001) was derived from its platform technology termed A‐TAP (Antibody-Targeted Anti-Vascularization Payload). SYN001 is currently in preclinical ...

Trimeris

Based in Morrisville, North Carolina, Trimeris was founded in 1993 by leading researchers in the study of the human immunodeficiency virus (HIV). Their work in the early 1990s led to a breakthrough in the fight against AIDS — an entirely new class of anti-HIV drugs called fusion inhibitors. In this section, you will find more information about our history, as well as the Trimeris mission, our le...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and are developing scientifically and clinically validated over the counter and prescription products that utilize TFS’ cultivated, sustainable, pharmaceutical-grade East Indian S...

ORA Clinical Research and Development

ORA Clinical Research and Development is a full service contract research organization based in North Andover, MA, which was founded by Dr. Mark B. Abelson, MD, and is committed to the research and development of medical devices and drugs for the ophthalmic and topical pharmaceutical industry. Specializing in the field of ophthalmology, ORA has gathered the top professionals and researchers in th...

Biota Inc

Biota, Inc. is an early-stage drug discovery company focused on the discovery and development of new classes of anti-infective and anti-cancer drugs. The Company’s discovery platform is referred to as N•MAX and is initially focused on improving existing nucleoside drugs to create novel compounds

Marinomed Biotechnologie GmbH

Marinomed is a biopharmaceutical company discovering and developing innovative anti-viral and immunological treatments. Marinomed develops therapies against respiratory diseases based on its innovative anti-viral respiratory technology platform mavirex. Safety and efficacy of the mavirex technology have already been proven in clinical trials. The huge potential of the technology is reflected by...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

Cytheris SA

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation.  These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transp...

Gibson Oncology, LLC

Gibson is a private oncology drug development company dedicated to bringing its novel, cost-effective, and very well-tolerated Indeno anti-cancer treatments to market. Gibson intends to develop these novel anti-cancer drugs in advanced-stage cancer patients as single agent and in combination treatments with both immunotherapy and targeted therapies.

Indena USA Inc.

Indena is the world's leading company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, manages cultivation, manufacturing, and distribution operations in more tha...

Vida Labs

Vida means Life in Latin. The motto of the company is ‘Injecting Life into the hearts of people through innovative quality pharmaceutical products creating a healthier world to live' Vida Laboratories has its corporate office in Bangalore , which is the silicon valley of India . Vida Laboratories is formed by young entrepreneurs. It is a 100% export oriented company focusing primarily in Asia Pa...

GeNO LLC

GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and ...

Marshall Edwards

Marshall Edwards, Inc. ('MEI') is a pharmaceutical company dedicated to the field of cancer therapy (oncology).MEI is developing a range of anti-cancer therapies that represents the next generation of oncology drugs - multiple signal transduction regulators (abbreviated as 'MSTRs') that reach to the heart of the cancer process.The source of this new range of drugs is a family of chemicals, discove...

AiCuris GmbH & Co.KG

"AiCuris (name derived from 'anti-infective cures') is a pharmaceutical company focused on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. AiCuris has its roots in Bayer's long history of successful anti-infective drugs. Spun out in 2006 AiCuris owns a broad portfolio of R&D progra...

Aeploa Co., Ltd

Founded in 1993, Apeloa (Kangyu) is a leading pharmaceutical company in China engaged in research, development and manufacture of synthetic and biological medicines, drug formulations as well as customer service for preparation of API and intermediates.Its products include four categories: anti-tumor medicine, anti-virus medicine, cardiovascular medicine and veterinary drugs.Apeloa (Kangyu) operat...

Prosidion Ltd

(OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Ph...

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

PolyMedix

PolyMedix is the leader in developing biomimetics - novel small molecule, oligomer and polymer protein-mimetic drugs for membrane protein and protein:protein targets. PolyMedix has a proven computational technology platform which was used to develop its first program: a line of unique anti-infective drugs for which bacterial resistance is highly unlikely to develop. Proteins are the machinery of ...

DeuteRx, LLC

DeuteRx has pioneered ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. The development of the single, preferred enantiomer from the parent...

Carbylan BioSurgery, Inc.

Carbylan (www.carbylan.com) was founded in 2005 to develop and market medical devices and device/drug combination products based on novel chemically engineered polymer systems incorporating hyaluronic acid, a well-known polysaccharide widely present in the human body. Its initial market focus is therapeutic medical devices and combination products to treat...

Microbia Incorporated

Microbia is a privately held biotechnology company that is harnessing the regulatory circuitry that governs microbial physiology and metabolism to develop a new generation of anti-infective therapeutics, as well as pioneering innovations in biomanufacturing. Our platform technologies are based on proprietary knowledge of the physiological changes made by microbes as they sense and adapt to changes...


More From BioPortfolio on "A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks